Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Phase 3

Completed

Conditions: Pneumococcal Disease

First Posted Date: 2020-11-24

Last Posted Date: 2024-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 839

Registration Number: NCT04642079

Locations: 🇺🇸
Northwest Arkansas Pediatrics, Fayetteville, Arkansas, United States
🇺🇸
The Children's Clinic of Jonesboro, P.A., Jonesboro, Arkansas, United States
🇺🇸
The Children's Clinic, Jonesboro, Arkansas, United States

and more 35 locations

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

Phase 2

Terminated

Conditions: Achondroplasia

First Posted Date: 2020-11-20

Last Posted Date: 2024-02-15

Lead Sponsor: Pfizer

Target Recruit Count: 60

Registration Number: NCT04638153

Locations: 🇺🇸
Ocean Sleep Medicine, Irvine, California, United States
🇺🇸
MemorialCare Sleep Disorders Center at Long Beach Memorial Medical Center, Long Beach, California, United States
🇺🇸
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States

and more 11 locations

STUDY OF TALAZOPARIB MONOTHERAPY IN CHINESE PARTICIPANTS WITH ADVANCED SOLID TUMORS

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: talazoparib

First Posted Date: 2020-11-19

Last Posted Date: 2023-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT04635631

Locations: 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

PHARMACOKINETIC CHARACTERIZATION OF PF-06651600 IN CHINESE ADULT PARTICIPANTS

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-06651600

First Posted Date: 2020-11-18

Last Posted Date: 2021-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT04634565

Locations: 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
North District of Peking University Third Hospital, Beijing, China

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07258669
Drug: Placebo

First Posted Date: 2020-11-16

Last Posted Date: 2024-02-21

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04628793

Locations: 🇺🇸
QPS-MRA, LLC-Main Office, South Miami, Florida, United States

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Non-small-cell Lung Cancer
Urothelial Carcinoma
Colorectal Carcinoma
Ovarian Carcinoma
Squamous Cell Carcinoma of the Head and Neck
Renal Cell Carcinoma

First Posted Date: 2020-11-16

Last Posted Date: 2024-07-29

Lead Sponsor: Pfizer

Target Recruit Count: 37

Registration Number: NCT04628780

Locations: 🇺🇸
City of Hope Investigational Drug Service (IDS), Duarte, California, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 10 locations

Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07304814

First Posted Date: 2020-11-13

Last Posted Date: 2021-01-06

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT04627532

Locations: 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections

Completed

Conditions: Gram Negative Infections

Interventions: Drug: Ceftazidime-avibactam

First Posted Date: 2020-11-13

Last Posted Date: 2024-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 189

Registration Number: NCT04628572

Locations: 🇮🇳
Fortis Hospital, Bhandup West, India
🇮🇳
Apollo Hospital, Hyderabad, India
🇮🇳
Gleneagles Global Hospitals, Chennai, India

and more 4 locations

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Phase 3

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: tofacitinib

First Posted Date: 2020-11-10

Last Posted Date: 2025-06-29

Lead Sponsor: Pfizer

Target Recruit Count: 120

Registration Number: NCT04624230

Locations: 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of California, San Francisco Benioff Children's Hospital, San Francisco, California, United States
🇺🇸
University of California, San Francisco Pediatric Clinical Research Center (PCRC), San Francisco, California, United States

and more 73 locations

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: PF-06882961
Drug: Rosuvastatin
Drug: Midazolam

First Posted Date: 2020-11-09

Last Posted Date: 2023-12-01

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT04621227

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy